The Europe Controlled Release Drug Delivery Market should witness market growth of 10.2% CAGR during the forecast period (2023-2030).
The past few years have seen increased pharmaceutical investment in many nations owing to the rising demand for medicines and treatments. Theconsistently expanding R&D spending of pharmaceutical companiesis directed at forming effective treatments for noncommunicable chronic problems, including cancer and diabetes.
Drug delivery devices are being used more frequently as a result of the rising cancer burden. Because patients could not tolerate high doses and the side effects associated with high doses, the predominance of chronic illnesses led to an increase in the demand for controlled release drug delivery.
It is anticipated that, by 2025, the total number of cancer cases in the EU countries will increase from the 2.75 million instances reported in 2015 to more than 3.1 million cases annually due to demographic factors. In addition, more people than ever before are coping with cancer. In Europe, 16-17 million persons are believed to be either undergoing cancer treatment or have achieved long-term remission after treatment. This number is anticipated to increase dramatically during the following several years. 85% of deaths in the EU are caused by chronic diseases such as cardiovascular disease, cancer, diabetes, chronic respiratory disorders, and mental illness. These conditions make up the list of specific causes of mortality. All forms of cancer rank first among the leading causes of death in people under 65, while cardiovascular disease is first among those over 65.
Germany is a prominent market for controlled release drug deliveryin Europe, and its growth is largely related to growing R&D spending for developing cutting-edge drug delivery systems. The Nose-to-Brain-patch (N2B-patch), a project sponsored by the EU itself, aims to develop a revolutionary technology for the treatment of multiple sclerosis (MS) by developing a "nose to the brain" medication delivery system. This region's two most commercially successful products are transdermal patches and transdermal semisolids. Due to changes brought about by a decline in health care, the region is experiencing an increase in mortality from cardiovascular diseases. The market in this region willgrowfaster due to all these elements.
The Germany market dominated the Europe Controlled Release Drug Delivery Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $7,194.3 million by 2030. The UK market is registering a CAGR of 9.3% during (2023-2030). Additionally, The France market would display a CAGR of 11% during (2023-2030).
Based on Release Mechanism, the market is segmented into Feedback Regulated Drug Delivery Systems, Activation-modulated Drug Delivery Systems, Chemically Activated, Polymer Based Systems and Micro Reservoir Partition Controlled Drug Delivery Systems. Based on Technology, the market is segmented into Targeted Delivery, Coacervation, Micro Encapsulation, Transdermal, Implants, Wurster Technique and Others. Based on Application, the market is segmented into Oral Controlled-drug delivery Systems, Metered Dose Inhalers, Injectable, Transdermal & Ocular Patches and Infusion Pumps & Drug Eluting Stents. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Merck & Co., Inc., Alkermes PLC, Pfizer, Inc., Assertio Holdings, Inc. (Assertio Therapeutics, Inc.), Lonza Group AG (Capsugel), Colorcon, Inc. (BPSI Holdings LLC.), Corium, LLC (Gurnet Point Capital), Adare Pharma Solutions, and Coating Place, Inc.
The past few years have seen increased pharmaceutical investment in many nations owing to the rising demand for medicines and treatments. Theconsistently expanding R&D spending of pharmaceutical companiesis directed at forming effective treatments for noncommunicable chronic problems, including cancer and diabetes.
Drug delivery devices are being used more frequently as a result of the rising cancer burden. Because patients could not tolerate high doses and the side effects associated with high doses, the predominance of chronic illnesses led to an increase in the demand for controlled release drug delivery.
It is anticipated that, by 2025, the total number of cancer cases in the EU countries will increase from the 2.75 million instances reported in 2015 to more than 3.1 million cases annually due to demographic factors. In addition, more people than ever before are coping with cancer. In Europe, 16-17 million persons are believed to be either undergoing cancer treatment or have achieved long-term remission after treatment. This number is anticipated to increase dramatically during the following several years. 85% of deaths in the EU are caused by chronic diseases such as cardiovascular disease, cancer, diabetes, chronic respiratory disorders, and mental illness. These conditions make up the list of specific causes of mortality. All forms of cancer rank first among the leading causes of death in people under 65, while cardiovascular disease is first among those over 65.
Germany is a prominent market for controlled release drug deliveryin Europe, and its growth is largely related to growing R&D spending for developing cutting-edge drug delivery systems. The Nose-to-Brain-patch (N2B-patch), a project sponsored by the EU itself, aims to develop a revolutionary technology for the treatment of multiple sclerosis (MS) by developing a "nose to the brain" medication delivery system. This region's two most commercially successful products are transdermal patches and transdermal semisolids. Due to changes brought about by a decline in health care, the region is experiencing an increase in mortality from cardiovascular diseases. The market in this region willgrowfaster due to all these elements.
The Germany market dominated the Europe Controlled Release Drug Delivery Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $7,194.3 million by 2030. The UK market is registering a CAGR of 9.3% during (2023-2030). Additionally, The France market would display a CAGR of 11% during (2023-2030).
Based on Release Mechanism, the market is segmented into Feedback Regulated Drug Delivery Systems, Activation-modulated Drug Delivery Systems, Chemically Activated, Polymer Based Systems and Micro Reservoir Partition Controlled Drug Delivery Systems. Based on Technology, the market is segmented into Targeted Delivery, Coacervation, Micro Encapsulation, Transdermal, Implants, Wurster Technique and Others. Based on Application, the market is segmented into Oral Controlled-drug delivery Systems, Metered Dose Inhalers, Injectable, Transdermal & Ocular Patches and Infusion Pumps & Drug Eluting Stents. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Merck & Co., Inc., Alkermes PLC, Pfizer, Inc., Assertio Holdings, Inc. (Assertio Therapeutics, Inc.), Lonza Group AG (Capsugel), Colorcon, Inc. (BPSI Holdings LLC.), Corium, LLC (Gurnet Point Capital), Adare Pharma Solutions, and Coating Place, Inc.
Scope of the Study
By Release Mechanism
- Feedback Regulated Drug Delivery Systems
- Activation-modulated Drug Delivery Systems
- Chemically Activated
- Polymer Based Systems
- Micro Reservoir Partition Controlled Drug Delivery Systems
By Technology
- Targeted Delivery
- Coacervation
- Micro Encapsulation
- Transdermal
- Implants
- Wurster Technique
- Others
By Application
- Oral Controlled-drug delivery Systems
- Metered Dose Inhalers
- Injectable
- Transdermal & Ocular Patches
- Infusion Pumps & Drug Eluting Stents
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Johnson & Johnson
- Merck & Co., Inc.
- Alkermes PLC
- Pfizer, Inc.
- Assertio Holdings, Inc. (Assertio Therapeutics, Inc.)
- Lonza Group AG (Capsugel)
- Colorcon, Inc. (BPSI Holdings LLC.)
- Corium, LLC (Gurnet Point Capital)
- Adare Pharma Solutions
- Coating Place, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Europe Controlled Release Drug Delivery Market by Release Mechanism
Chapter 6. Europe Controlled Release Drug Delivery Market by Technology
Chapter 7. Europe Controlled Release Drug Delivery Market by Application
Chapter 8. Europe Controlled Release Drug Delivery Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Johnson & Johnson
- Merck & Co., Inc.
- Alkermes PLC
- Pfizer, Inc.
- Assertio Holdings, Inc. (Assertio Therapeutics, Inc.)
- Lonza Group AG (Capsugel)
- Colorcon, Inc. (BPSI Holdings LLC.)
- Corium, LLC (Gurnet Point Capital)
- Adare Pharma Solutions
- Coating Place, Inc.
Methodology
LOADING...
